THE EFFECT OF NEBULIZED AZITHROMYCIN AS THERAPY FOR BRONCHOPULMONARY DYSPLASIA

Launched by ALEXANDRIA UNIVERSITY · Sep 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called nebulized azithromycin in preventing a serious lung condition known as bronchopulmonary dysplasia (BPD) in very low birth weight preterm infants. BPD often affects babies born before 32 weeks of pregnancy who need help with breathing. The trial will compare the effects of azithromycin to a placebo, which is an inactive substance that looks like the medicine but doesn’t have any effect, to see if the drug can help these vulnerable infants.

To be eligible for this study, infants must be born before 32 weeks of pregnancy and weigh less than 1500 grams (about 3.3 pounds). They also need to be receiving respiratory support, like oxygen or a ventilator, by the time they are 7 days old. The trial is currently looking for participants, and it’s important to note that babies with certain health issues, like heart defects or major congenital abnormalities, will not be included. Families who participate will be helping researchers learn more about how to improve care for premature infants with breathing difficulties.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Gestational age less than 32 weeks and birth weight less than 1500 g.
• • 2. Infants who are still in need of respiratory support at day 7 of life (intubated, or by non-invasive mechanical ventilation, including CPAP and high-flow nasal cannula, or any form of oxygen therapy).
• Exclusion Criteria:
• • Gestational age ≥ 32 weeks.
• • Newborns with congenital cyanotic heart diseases.
• • Obvious major congenital malformations, known syndromes or chromosomal anomalies.
• • Infants with signs compatible with the diagnosis of necrotizing enterocolitis (NEC) in the first week of life.
• • Current use of steroids.